TSBX turnstonebio.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
The price action of Turnstone Biologics (TSBX) based on the EV/EBITDA metric is . Turnstone Biologics is implementing an innovative method of modifying autologous lymphocytes to destroy neoplasms. However, international conflicts may hinder the procurement of reagents and the protection of intellectual property rights. While the company currently generates no revenue, future income will be based on exclusive patents for the treatment of solid tumors.
פילוחי נתונים אנליטיים מרוכזים עבור turnstonebio.com (TSBX)
The EV/EBITDA multiple assesses the total value of a business relative to its operating profit before interest and taxes. The trend in the EV/EBITDA multiple for Turnstone Biologics (TSBX) reflects a market revaluation of assets compared to generated cash flow. For Turnstone Biologics (TSBX), this metric is critical, as the absence of regular revenue and dependence on clinical trial outcomes make the enterprise value sensitive to debt load.
